🧬 Pharma Marketing, Compounding, and the GLP-1 Gray Zone | Sabrina Johnson (2/4)
The Biotech Startups Podcast · 2026-05-21 · 28 min
Episode notes
The Biotech Startups Podcast is powered by Excedr—helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network—special savings, promotions, and more. Explore these offers today: "Formulation matters. I can put the same active pharmaceutical ingredient in the exact same concentration in 20 different formulations and have 20 different outcomes." In this episode of The Biotech Startups Podcast, Jon Chee continues his conversation with Sabrina Johnson, President and CEO of DARÉ Bioscience. Sabrina traces her path from a name-tag encounter that led her to Advanced Tissue Sciences to joining Cypress Bioscience in 1998. She unpacks pharmaceutical marketing regulation, the medical-regulatory-legal review process, and the gray zone of compounded GLP-1s — including DARÉ's decision to make its sildenafil cream available via 503B rather than leave women without a validated option.